COMMUNIQUÉS West-GlobeNewswire

RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
04/02/2026
Results Support TAMP’s Novel Approach to Targeted, Pressure-Mediated Chemotherapeutic Delivery and Reinforces its Potential to Provide Individualized, Optimized Drug-Delivery MOUNTAIN VIEW, Calif., Feb. 04, 2026 (GLOBE [...]
Spur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at 22nd Annual WORLDSymposium™
04/02/2026
Two-year follow-up data demonstrate sustained benefit, including improvements in pain, fatigue and bone health, following single low dose of avigbagene parvec (FLT201) Robust improvements in lyso-Gb1, a surrogate [...]
Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit
04/02/2026
Highlights: Strategic Validation: Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent late-stage clinical [...]
Experience Truly Natural Results: Aesthetics International Leads the Region with Expressive Botox Expertise
04/02/2026
The Era of "Invisible" Enhancements: Aesthetics International Introduces Expressive Botox to Dubai’s Elite Wellness Scene DUBAI, United Arab Emirates, Feb. 04, 2026 (GLOBE NEWSWIRE) -- As Dubai solidifies its reputation [...]
Levicept Announces the Appointment of James Sandy as Chief Development Officer
04/02/2026
Leadership Team Strengthened to Support Clinical Development of LEVI-04 for Osteoarthritis SANDWICH, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of [...]
Novo Nordisk has published its annual report for 2025
04/02/2026
Bagsværd, Denmark, 4 February 2026 – Today, Novo Nordisk A/S has issued its 2025 annual report. The report is available here: https://www.novonordisk.com/investors/annual-report.html and is attached in iXBRL format. [...]
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan
04/02/2026
A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Curium Group today [...]
ONWARD Medical Announces First Participant Enrolled in Global Pivotal Study Evaluating ARC-IM System to Address Blood Pressure Instability After Spinal Cord Injury
04/02/2026
Empower BP is a landmark global pivotal study evaluating the safety and effectiveness of the implantable ARC-IM ® System to address blood pressure instability after spinal cord injury (SCI) Blood pressure instability is [...]
Michigan Integrative Health Expands Stem Cell Therapy Services to Welcome Canadian Patients
04/02/2026
DETROIT, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Michigan Integrative Health Stem Cells , a leading provider of stem cell therapy and regenerative medicine in Shelby Township, Michigan, announces the expansion of its service [...]
Novo Nordisk initiates 2026 share repurchase programme
04/02/2026
Bagsværd, Denmark, 4 February 2026 –The execution of Novo Nordisk A/S’ overall share repurchase programme for 2026 of up to DKK 15 billion will be initiated on 4 February 2026. As part of this, Novo Nordisk A/S today [...]
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
04/02/2026
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +8% (cc 1 , +8% USD) with core operating income 1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from priority brands [...]
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
04/02/2026
Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPF Findings extend MiNK’s iNKT platform into chronic fibrotic lung disease and support immune restoration strategies in IPF, [...]
Herz P1 Smart Scale: 8-Electrode Body Composition Tracking Device With 56 Metrics — Product Information Updated for 2026
04/02/2026
An informational overview examining dual-frequency BIA technology, segmental body composition analysis, no subscription fee access, and what consumers researching home wellness tracking devices consider when comparing [...]
BioStem Technologies Highlights Alignment with FDA’s Openness to Bayesian Statistical Approaches in Clinical Research
03/02/2026
POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived [...]
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
03/02/2026
Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026 GLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage [...]
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
03/02/2026
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry [...]
InnovAge Announces Financial Results for the Fiscal Second Quarter Ended December 31, 2025
03/02/2026
DENVER, Feb. 03, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/02/2026
SAN FRANCISCO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03/02/2026
SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)- [...]

Pages